SCHEDULE: Guardian Pharmacy Insiders Sell 5.88M Shares

Key shareholders of Guardian Pharmacy Services, Inc. sold 5.88 million Class A common shares, including an underwriter option, and are subject to a 180-day lock-up period.

Summary

• Reporting Persons, including Bindley Capital Partners I, LLC, William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC, John Ackerman, Cardinal Equity Fund, L.P., Fred P. Burke, David K. Morris, and G. Kendall Forbes, collectively sold 5,880,000 shares of Class A common stock on March 20, 2026.
• This sale was executed pursuant to an underwriting agreement dated March 18, 2026, and included an additional 900,000 shares purchased by underwriters through their option.
• Following the sale, the Reporting Persons collectively beneficially own 17,929,985 shares of Class A common stock, representing approximately 36.0% of the class.
• The beneficial ownership calculation is based on 49,781,181 shares of Class A common stock, which includes 36,259,762 shares outstanding as of March 13, 2026, and 13,521,419 shares expected to be issued upon the automatic conversion of Class B shares on March 28, 2026.
• Reporting Persons are subject to a 180-day lock-up agreement from March 18, 2026, restricting further direct or indirect sales, transfers, or hedging of common stock or convertible securities without prior written consent from BofA Securities, Inc. and Jefferies LLC.
• Class B common stock will automatically convert into Class A common stock on a one-for-one basis in substantially equal tranches on March 28, 2026, and September 27, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a slightly negative sentiment due to the significant insider selling, which, despite being part of an offering, can raise questions about long-term confidence among key investors. The upcoming share conversion also introduces potential for increased float and volatility.

Positives

• The sale of shares by reporting persons indicates liquidity for these investors.
• The exercise of the underwriters' option to purchase an additional 900,000 shares suggests strong market demand for the shares offered in the secondary offering.

Negatives

• Significant insider selling by key investors could be perceived negatively by the market, potentially signaling a lack of confidence or a desire to diversify holdings.
• The 180-day lock-up agreement restricts the reporting persons' ability to sell additional shares, limiting their liquidity in the short term.

Risks

• The market may interpret the substantial sale of shares by key investors as a negative signal, potentially impacting the stock price.
• The upcoming automatic conversion of Class B to Class A shares will increase the public float of Class A shares, which could lead to increased supply and potential price volatility if a large number of these newly converted shares are sold.

Future Outlook

The company anticipates the automatic conversion of Class B common stock into Class A common stock in two substantially equal tranches on March 28, 2026, and September 27, 2026, which will increase the number of outstanding Class A shares.

Industry Context

StockSavvy.ai notes that significant insider selling, even in a secondary offering, can sometimes be viewed with caution by the market, as it may suggest that large shareholders are taking profits or diversifying their holdings. However, the exercise of the underwriters' option indicates strong market appetite for the shares at the offering price.

Stakeholder Impact

• Shareholders: The sale by significant holders could impact market perception and potentially the stock price. The conversion of Class B to Class A shares will increase the public float of Class A shares.
• Reporting Persons: Gained liquidity from the sale but are restricted from further sales for 180 days due to lock-up agreements.

Next Steps

• Automatic conversion of Class B common stock to Class A common stock on March 28, 2026 (first tranche).
• Automatic conversion of Class B common stock to Class A common stock on September 27, 2026 (second tranche).
• Reporting Persons are subject to a 180-day lock-up period from March 18, 2026, restricting further sales.

Key Dates

Recommendation

The significant insider selling, while providing liquidity to the reporting persons, introduces uncertainty regarding their long-term commitment and could exert downward pressure on the stock. However, the exercise of the underwriters' option suggests underlying market demand. The upcoming conversion of Class B shares to Class A will increase the float, which could lead to further price adjustments. Given these mixed signals and the lock-up period, a 'hold' recommendation is prudent until the market fully digests these changes and the impact of the increased float is clearer.

Keywords

Guardian Pharmacy Services, Schedule 13D, Insider Selling, Class A Common Stock, Class B Common Stock, Share Conversion, Lock-up Agreement, Secondary Offering, Bindley Capital Partners, Pharmacy Investors, Cardinal Equity Fund